

Clinical Pharmacy Program Guidelines for Isturisa

Program	Prior Authorization
Medication	Isturisa (osilodrostat)
Markets in Scope	Arizona, California, Hawaii, Maryland, Nevada, New Jersey, New York, New York EPP, Pennsylvania-CHIP, Rhode Island, South Carolina
Issue Date	6/2020
Pharmacy and Therapeutics Approval Date	6/2020
Effective Date	8/2020

1. Background:

Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

2. Coverage Criteria:

A. Initial Authorization

1. Isturisa will be approved based on **both** of the following criteria:

a. Diagnosis of Cushing’s disease

-AND-

b. **One** of the following:

(1) Patient is not a candidate for pituitary surgery

-OR-

(2) Pituitary surgery has not been curative

Authorization will be issued for 12 months.

B. Reauthorization

1. Isturisa will be approved based on the following criterion:

- a. Documentation of positive response to Isturisa therapy

Authorization will be issued for 12 months.

C. NCCN Recommended Regimens

1. Initial Authorization

- a. **Isturisa** will be approved for uses not outlined above if supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium.

Authorization will be issued for 12 months.

2. Reauthorization

- a. **Isturisa** will be approved based on the following criterion:

- (1) Documentation of positive clinical response to Isturisa therapy

Authorization will be issued for 12 months.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Isturisa [Package Insert]. Lebanon, NJ: Recordati Rare Disease, Inc.; March 2020.

Program	Program type - Prior Authorization
Change Control	
6/2020	New program